BRIGHTWAY
4.11.2021 18:07:09 CET | Business Wire | Press release
SUZHOU BRIGHTWAY released the latest flagship Electric Scooter NAVEE N65 on Xiaomi Youpin crowdfunding website, and raised more than €430,000 successfully.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104006077/en/
BRIGHTWAY has a professional design and R&D team with rich experience in micro-mobility. Based on the thorough understanding of customers’ requirements and pain points, as well as the full consideration of practicality, safety and comfort at the stage of design, BRIGHTWAY team finally launched NAVEE N65 with the following key features, making the N65 perfect and the most suitable for commute or joy ride.
65KM Ultra-long Range : Travelling up to 65 km on a single charge, the N65 can make the charging frequency from one time per day to one time per week for the customers with short distance commuting within 10km.
10 Inch Big Tires: In order to deliver extremely comfortable and smooth riding experience for riders, the N65 is equipped 10-inch big off-road pneumatic tires.
Rated Power 500watt Brushless Motor: It improves the climbing performance up to 25%, and supports three different speed level (1st level to 15km/h, 2nd level to 25km/h, 3rd level to 32km/h). The maximum speed can reach 32 km/h. (Noted: The maximum speed varies according to the laws and regulations of different regions, please refer to the requirements of the laws and regulations)
Double Rotation Folding System: With innovative design of folding neck and handlebar, the N65 makes the pre-assembling and folding more convenient.
Features:
- Ultra-long range up to 65 km;
- Innovative design of double rotation folding system;
- 25% superb uphill climbing ability;
- 10 inch off-road pneumatic tires;
- Rated power 500watt brushless motor;
- Max loading weight 120kg;
- 17cm wide magnesium alloy deck;
- Front E-ABS brake with rear disc brake;
- Separated big HMI;
- Three speed levels;
- Support cruise control and energy recovery with APP.
- Ultra-bright front light
In middle November, NAVEE N65 will be launched at European market with only priced at €649. And the limited-time promotion price is just €599.
About BRIGHTWAY
SUZHOU BRIGHTWAY Intelligent Technology Co., Ltd is an innovative high-tech enterprise focusing on R&D, production and distribution of E-scooters and E-bikes. Equipped with advanced technology and strong R&D strength, SUZHOU BRIGHTWAY Intelligent Technology Co., Ltd. now is also an emerging Xiaomi ecological chain company.
For more information, please visit http://navee-tech.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104006077/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom